News By Tag Industry News News By Place Country(s) Industry News
|  Just Released: "Arimidex (Breast Cancer) - Analysis and Forecasts to 2020"New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
By: Fast Market Research, Inc. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Scope * Therapy area profile including patient population for the US, EU5 and Japan (seven major markets) * Analysis and review of Arimidex including sales data * Qualitative and quantitative assessment of market space * Analysis of the trends, drivers and restraints shaping and defining the markets * In-depth analysis of Arimidex including efficacy, safety, pricing, competition and other details which influence its sales potential * Detailed sales forecasts from 2002-2020 for Arimidex in the seven major markets Reasons to buy * Understand and capitalize by identifying products that are most likely to ensure a robust return * Stay ahead of competition by understanding the changing competitive landscape * Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential * Make more informed business decisions from insightful and in-depth analysis of the drug's performance * Examine the historical sales performance of a drug in seven major markets * Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets Arimidex, Breast Cancer, Anastrazole, Sales forecast, Aromatase Inhibitor, Phase III, Phase 3, Competitors to , Femara, Xeloda, Afinitor, Faslodex, and Nolvadex, Astrazeneca Partial Table of Contents: 1 Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Breast Cancer Market 2.2 Epidemiology 2.3 Etiology and Risk Factors 2.3.1 Age and Gender 2.3.2 Genetic Inheritance 2.3.3 Hormone Replacement Therapy 2.3.4 Radiation 2.3.5 Obesity 2.3.6 Alcohol Consumption 2.3.7 Late Child Birth 2.3.8 Use of Birth Control Pills 2.4 GlobalData Report Guidance 3 Breast Cancer: Market Characterization 3.1 Breast Cancer Market 3.2 Breast Cancer Market Forecasts and CAGR 3.3 Drivers of Breast Cancer Market 3.3.1 Breast Cancer: Most Frequent Cancer in Women 3.3.2 Increasing Breast Cancer Incidence Rate 3.3.3 Decreasing Breast Cancer Mortality Rate 3.3.4 High Survival Rates of Breast Cancer 4 Staging of Breast Cancer: Introduction 4.1 Distribution of Patients by Stages 4.1.1 Stages 5 Predictive Biomarker in the Treatment of Breast Cancer 6 Treatment Options of Breast Cancer 6.1 Stage 0 Breast Cancer 6.2 Early Stage Breast Cancer (Excluding Stage 0) 6.3 Metastatic Breast Cancer (MBC) 6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 6.3.2 Cytotoxic Chemotherapy 6.3.3 Management of Patients with HER-2 Positive Patients 7 Arimidex 7.1 Introduction 7.2 Mechanism of Action 7.3 Clinical Studies 7.4 Approval History of Arimidex 7.5 Factors Affecting Sales of Arimidex 7.5.1 Arimidex Vs Nolvadex 7.5.2 Safety and Toxicity Profile 7.5.3 Arimidex Competitive Advantage 7.5.4 Patent Expiry 7.6 Drug Evaluation 7.6.1 Drug Risk Benefit Score 7.6.2 Intensity of Competition 7.7 Sales Forecast of Arimidex 7.7.1 Target Patient Pool of Arimidex 7.7.2 Dosing 7.7.3 Market Penetration 7.7.4 Annual Cost of Therapy 7.7.5 Sales Projections of Arimidex 8 Appendix 8.1 Market Definitions 8.2 Abbreviations 8.3 Research Methodology 8.3.1 Coverage 8.3.2 Secondary Research 8.3.3 Forecasting 8.3.4 Number of Patients Approved to Take the Drug 8.3.5 Net Penetration of Drug 8.3.6 Net Annual Dosing 8.3.7 Annual Cost of Therapy 8.4 Drug Sales Estimates Model 8.5 Contact Us 8.6 Disclaimer 8.7 Sources List of Tables 1.1 List of Tables Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 Table 2: Five-Year Relative Survival Rates, 2005, By Stages Table 3: Arimidex Approval History Table 4: Drug Risk Benefit Score of Arimidex Table 5: Annual Cost of Therapy of Arimidex, 2011 Table 6: Arimidex, Breast Cancer, Global, Sales Estimates ($m), 2002-2020 Table 7: Arimidex, Breast Cancer, The US, Sales Estimates ($m), 2002-2020 Table 8: Arimidex, Breast Cancer, The UK, Sales Estimates ($m), 2002-2020 Table 9: Arimidex, Breast Cancer, France, Sales Estimates ($m), 2002-2020 Table 10: Arimidex, Breast Cancer, Germany, Sales Estimates ($m), 2002-2020 Table 11: Arimidex, Breast Cancer, Italy, Sales Estimates ($m), 2002-2020 Table 12: Arimidex, Breast Cancer, Spain, Sales Estimates ($m), 2002-2020 Table 13: Arimidex, Breast Cancer, Japan, Sales Estimates ($m), 2002-2020 List of Figures 1.2 List of Figures Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010-2020 Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 Figure 10: Broad Classification of Breast Cancer, By Type Figure 11: Classification of Non-Invasive Breast Cancer, By CIS Figure 12: Classification of Invasive Breast Cancer, By Stages Figure 13: Classification of Invasive Breast Cancer, By Treatment Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer Full Table of Contents is available at: -- http://www.fastmr.com/ About GlobalData GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number